Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharma (AMPH) Misses Q1 EPS by 3c
May 9, 2018 4:14 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of $0.05, $0.03 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $58.4 million versus the consensus estimate of $60.75 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More